Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

Children's Oncology Group25 enrolled

Overview

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

OBJECTIVES: * To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression. * To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors. * To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples. OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Brain and Central Nervous System Tumors Kidney Cancer

Interventions

DNA analysisGENETIC

gene expression analysisGENETIC

mutation analysisGENETIC

protein expression analysisGENETIC

Eligibility

Sex: ALLMax age: 120 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Tumor samples from patients diagnosed with rhabdoid tumors * Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors * Any source of DNA from BRG1-negative tumors (tumors, blood, etc.) * Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

Absence or presence BRG1 and BRM expression in rhabdoid tumors

Mechanism of suppression of BRG1 and BRM genes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.